First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.

Abstract

In prolactin-secreting giant adenomas, cabergoline treatment is the first line approach. Surgery and/or radiotherapy are indicated when the tumour is resistant to medical treatment and continues growing, causing visual field impairment. Data concerning other therapeutic approach are scanty. Although PRL-secreting tumours may express somatostatin receptors type 2, 3 and 5, somatostatin analogs treatment is generally ineffective and peptide receptor radionuclide therapy (PRRT) has never been reported. A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. No side effects were reported. This is the first report on the effectiveness and safety of PRRT with radio-labelled somatostatin analogs in a patient with aggressive giant prolactinoma resistant to conventional treatment.

• Authors: S Baldari, F Ferraù, C Alafaci, A Herberg, F Granata, V Militano, F M Salpietro, F Trimarchi, S Cannavò
• Journal: Pituitary (Pituitary) Vol. 15 Suppl 1 Pg. S57-60 (Dec 2012) ISSN: 1573-7403 [Electronic] United States
• PMID: 22222543 (Publication Type: Case Reports, Journal Article)

Chemical References

• indium-111-octreotide
• Octreotide

Topics

• Female
• Humans
• Middle Aged
• Octreotide (analogs & derivatives, therapeutic use)
• Prolactinoma (diagnostic imaging, drug therapy)
• Radionuclide Imaging